| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e4afb1530bd6dd6420ba72c97597ef00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_df02dc2eab1779ebc7dfb5accf94318b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed3c2f63a5b1c705b1b389a6f1f1f7c8 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 |
| filingDate |
2020-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e73a40331d95e613ee2f724652abc4fd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e8a92116c24b022b81f6aac28f185447
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e371adacec7cf21341798268e0d5be5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_928766c486ee87f497cc8c699bbb9c82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ddef2fe5f996b858138cdf5a1a1f53e |
| publicationDate |
2022-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022168394-A1 |
| titleOfInvention |
Methods of inducing or restoring immune tolerance |
| abstract |
Some rare and very severe autoimmune conditions are of hereditary origin such as APECED and IPEX syndrome due to altered negative selection of autoreactive T cells in the thymus or absence of regulatory T cells (Treg). Innovative strategies based on the use of regulatory T cells have been developed. The inventors have now compared 7 different experimental protocols to identify the one allowing to get the most efficacy of Treg to treat Scurfy autoimmune syndrome, a severe autoimmune model mimicking IPEX syndrome. The optimized protocol comprised a preconditioning step using cyclophosphamide and a post-conditioning step using IL-2. Thus, to present invention relates to a method for the treatment of autoimmunity in patient in need thereof comprising the steps of i) administering the patient with an amount of cyclophosphamide, ii) then engrafting the patient with an amount of the population of Treg cells, and iii) finally administering the patient with an amount of IL-2. |
| priorityDate |
2019-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |